Patient Enrollment Begins in Third and Final Cohort of the P

Patient Enrollment Begins in Third and Final Cohort of the Phase 2 MATRICS-1 Clinical Study Evaluati

CLEVELAND--(BUSINESS WIRE)--Athersys, Inc. (NASDAQ: ATHX), a regenerative medicine company developing MultiStem® (invimestrocel) cell therapy for critical care indications, announces patient enrollment has begun in the third and final cohort in MATRICS-1, the Phase 2 clinical study evaluating MultiStem® in patients...

Related Keywords

Texas , United States , Texas Medical Center , Houston , University Of Texas , Memorial Hermann Hospital , Ellen Gurley , Charless Cox Jr , Dan Camardo , Uthealth Neurosciences , Technology Enterprise Consortium , D Bradley Mcwilliams School Of Biomedical Informatics , Corporate Communications , Department Of Defense , Linkedin , Memorial Hermann Health System , Harris Health Lyndonb Johnson Hospital , Memorial Hermann Foundation , Mcgovern Medical School , Facebook , Athersys Inc , Uthealth Harris County Psychiatric Center , Ut Health Services , Robert Cizik School Of Nursing , Twitter , Kathrineg Mcgovern Medical School , University Of Texas System Board Regents , Department Of Pediatric Surgery , Level One Trauma Center , Accountable Care Organization , Nasdaq , Texas Health Science Center , Memorial Hermann Texas Medical Center , Medical Technology Enterprise Consortium , Memorial Hermann , Hermann Texas Medical Center , Chief Executive Officer , Cynthia Mitchell Distinguished Chair , Glassell Family Distinguished Chair , Pediatric Surgery , Principal Investigator , Texas System Board , Health University , Robert Cizik School , Govern Medical School , Mcwilliams School , Biomedical Informatics , Harris County Psychiatric Center , Harris Health Lyndon , Southeast Texas , Greater Houston , Memorial Hermann Surgical Hospital First Colony , Memorial Hermann Surgical Hospital Kingwood , Memorial Hermann Rehabilitation , Private Securities Litigation Reform Act , Annual Report ,

© 2025 Vimarsana